LOGIN  |  REGISTER
Viking Therapeutics
Compass Therapeutics

Waystar to Present at Goldman Sachs Communacopia + Technology Conference

August 26, 2025 | Last Trade: US$36.17 0.46 1.29

LEHI, Utah and LOUISVILLE, Ky., Aug. 26, 2025 /PRNewswire/ -- Waystar (Nasdaq: WAY), a provider of leading healthcare payment software, announced today that Chief Executive Officer Matt Hawkins will present at the Goldman Sachs Communacopia + Technology Conference on Wednesday, September 10, 2025, at 3:05 p.m. PT.

Waystar will provide a live webcast of the event on its Investor Relations website at https://investors.waystar.com/news-events/events. A recording will also be available on the site after the event.

About Waystar

Waystar's mission-critical software is purpose-built to simplify healthcare payments so providers can prioritize patient care and optimize their financial performance. Waystar serves approximately 30,000 clients, representing over 1 million distinct providers, including 16 of 20 institutions on the U.S. News Best Hospitals list. Waystar's enterprise-grade platform annually processes over 6 billion healthcare payment transactions, including over $1.8 trillion in annual gross claims and spanning approximately 50% of U.S. patients. Waystar strives to transform healthcare payments so providers can focus on what matters most: their patients and communities. Discover the way forward at waystar.com.

Media Contact
Kristin Lee
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investor Contact
This email address is being protected from spambots. You need JavaScript enabled to view it.
502-238-9511

Viking Therapeutics

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page